Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function ...
Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
Doctors perform transurethral ultrasound ablation (TULSA) procedures using the TULSA-PRO system. This treats people with prostate disease, including prostate cancer or an enlarged prostate. New ...
Hosted on MSN
Profound Medical targets 70–75% revenue growth in 2025 as TULSA-AI and CAPTAIN trial progress fuel confidence
CEO Arun Swarup Menawat summarized that "our sales team has been stabilized. That, combined with our large and growing TULSA-PRO pipeline, continues to drive our confidence in our ability to deliver ...
Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback